Portfolio
The Cirna platform analyzes expressed transcripts in blood, detecting SNPs, indels, splice and fusion variants, and non-coding genome activity.
hepionpharma.comCrawled Nov 13, 2026
The Cirna platform analyzes expressed transcripts in blood, detecting SNPs, indels, splice and fusion variants, and non-coding genome activity.
Hepatocellular carcinoma (HCC) is the major type of liver cancer, accounting for 85-90% of all cases. Metabolic dysfunction-associated steatohepatitis (MASH), hepatitis virus infection, and alcohol consumption all are major causes of HCC.
“Panels are not cumulative across studies: the 2022 study reported 5,480 variants; the 2025 panel tested 288.”
Hepion Pharmaceuticals, Inc., 22 West Street Suite 1B Red Bank, NJ 07701 OTCQB: HEPA 732-505-7432 info@hepionpharma.com
Hepion seeks professionals with a record of delivering results to develop novel antiviral therapies.
Hepion leadership brings a management team with completed public-company restructuring experience, operating against a resolved legacy asset register and a reconstituted board for indications of important unmet need.
Hepion Pharmaceuticals, Inc. focuses on early liver cancer detection. Its board and management were reconstituted in March 2026 by an investor group with prior public-company turnaround experience, and management compensation aligns with outside shareholders via equity.
Management plans to build a portfolio in immunology, inflammation, and related areas, applying its prior restructuring approach of human-validated assets, clear regulatory paths, and milestone-based deals.
Hepion Pharmaceuticals develops diagnostics and therapies for liver, immune, and inflammatory diseases. Its subsidiary, Gravitas Life Sciences, advances immunology and inflammation treatments, including a buccal film opioid antagonist and an oral anti-inflammatory antibody.
Hepion Pharmaceuticals reports FDA feedback suggesting GV104 (16 mg nalmefene buccal film) may demonstrate prophylactic protection against fentanyl-induced cardiac arrest. In a virtual trial of 200 subjects, a single dose taken 15 minutes before exposure prevented all lethal fentanyl-induced cardiac arrests at known lethal intravenous doses. The feedback supports further development of GV104 as a preventive treatment.
Hepion Pharmaceuticals receives FDA feedback supporting its 505(b)(2) regulatory pathway for **GV104**, a treatment candidate for **gambling disorder**. The feedback confirms the company’s Phase 2 proof-of-concept trial design is appropriate. Hepion plans to submit an **Investigational New Drug (IND) application in 2027** to advance clinical testing.
Hepion Pharmaceuticals secures positive feedback from the FDA’s Division of Psychiatry on its Type B pre-IND meeting request. The responses address the regulatory pathway, nonclinical data package, and the design of an upcoming Phase 2 study. The company now moves forward with its development plans under the guidance provided.
Hepion Pharmaceuticals secures a positive FDA response for its investigational drug **GV104**, targeting **gambling disorder**, a condition lacking approved treatments. The FDA’s Division of Psychiatry addressed regulatory pathways, nonclinical data, and the design of a planned **Phase 2 study** in its written feedback. The company now advances toward clinical trials under the guidance provided.
Hepion Pharmaceuticals acquires Gravitas Life Sciences, gaining access to **GV104**, a clinical-stage opioid countermeasure under a **505(b)(2) regulatory pathway** with an active investigational new drug (IND) application. The deal also includes **GV023**, an oral formulation of an approved anti-TNF antibody. The company provides a corporate update alongside the acquisition announcement.
Hepion Pharmaceuticals acquires Gravitas Life Sciences, a clinical-stage biotech firm focused on immunological and inflammatory disease treatments. The deal expands Hepion’s pipeline with Gravitas’ ongoing research programs. Sireesh Appajosyula is appointed CEO of the combined entity.

Hepion Pharmaceuticals is a biotechnology company developing an assay for early liver cancer in high-risk cirrhotic patients and therapeutic candidates.